Physician profile
Frank E Trogolo
NPI 1013913383
$6,549.63
in general payments reported to CMS, 2019-2025
30 companies · $433 in 2025
The $433 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $598 · 2021: $1,037 · 2022: $2,758 · 2023: $749 · 2024: $255 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,126.24 | 2021-2023 | Da Vinci Surgical System |
| Abbvie INC. | $791.86 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $516.91 | 2019-2025 | |
| Hologic Sales and Service, LLC | $512.79 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $364.06 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $304.25 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $247.40 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $164.78 | 2020-2025 | Zurzuvae |
| Exeltis, USA INC. | $157.13 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $145.78 | 2019-2023 | Injectafer |
| Therapeuticsmd, INC. | $131.40 | 2019-2022 | |
| Medical Device Business Services, INC. | $118.94 | 2020 | |
| Pfizer INC. | $116.21 | 2019-2024 | |
| Myovant Sciences INC. | $104.72 | 2021-2022 | |
| Ethicon US, LLC | $93.38 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $85.82 | 2021 | |
| Coopersurgical, INC. | $69.91 | 2021-2025 | Paragard T 380a |
| Scynexis, INC. | $67.27 | 2022 | |
| Myriad Women'S Health, INC. | $63.40 | 2023 | Myrisk |
| Avion Pharmaceuticals | $60.26 | 2020-2022 | |
| Organon LLC | $45.35 | 2022 | |
| Amag Pharmaceuticals, INC. | $44.52 | 2019-2020 | |
| Allergan, INC. | $40.18 | 2019-2020 | |
| Lupin INC. | $39.93 | 2019-2021 | |
| Dysis Medical, INC. | $36.55 | 2020 | |
| Aspira Women'S Health INC | $32.78 | 2019-2020 | |
| Shield Therapeutics INC | $21.81 | 2024 | |
| Virtus Pharmaceuticals LLC | $17.71 | 2021 | |
| Lsi Solutions INC | $15.78 | 2021 | |
| Medtronic, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Trogolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.